alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
**Exhibit 23.3**

Consent of Independent Registered Public Accounting Firm 

We have issued ourreport dated February 25, 2010, with respect to Management’s Assertions on Compliance with specified servicing criteria set forth in Item 1122(d) of the Securities and Exchange Commission Regulation AB in the Annual Reports ofDiscover Card Master Trust I and Discover Card Execution Note Trust on Form 10-K for the year ended November 30, 2009. We hereby consent to the incorporation by reference of said report in the Registration Statements of Discover Bank, DiscoverCard Master Trust I and Discover Card Execution Note Trust on Forms S-3 (File No. 333-141703, File No. 333-141703-01 and File No. 333-141703-02). 

/s/ Grant Thornton LLP 

Dallas, Texas 

February 25, 2010
Sekirite Manje Lakay Ou

1. Pwopte 

Toujou lave manje ou, men ou, kontwa, ak zouti pou kwit manje.

• Lave men w nan dlo tyèd ak savon pou omwen de 20 segonn. Fè sa anvan ak apre ou manyen manje.

• Lave planch koupe ou yo, asyèt, fouchèt, kiyè, kouto, ak tèt kontwa avèk savon ki nan dlo cho. Fè sa apre ou fin itilize

avèk chak atik manje.

• Lave tout fwi ak legim.

• Pa lave vyann, bèt volay, pwason, oswa ze. Si dlo a aspèje soti nan evye a pandan w ap lave l, li ka pwopaje bakteri.

• Netwaye kouvèti sou tout bwat anvan ou louvri yo.

2. Separe (Kenbe Apa)

Kenbe manje ki pa kwit pou tet yo. Jèm ka gaye soti nan yon manje antre 

nan yon lot. 

• Kenbe vyann ki pa kwit, bèt volay, fwidmè, ak ze lwen lòt manje. Fè sa nan kawotchou manje, sak, ak frijidè.

• P a reutilize marinad yo itilize sou manje ki pa kwit sof si ou bouyi yo avan.

• Sèvi ak yon tablo koupe espesyal oswa plak pou manje ki pa kwit sèlman.

3. Kwit 

Manje bezwen vin cho epi rete cho. Chalè touye jèm.

• Kwit nan tanperati ki an sekirite:

‐ Bef, Kochon, Ti Mouton 145 °F 

‐ Pwason 145 °F 

‐ Vyann Bef, Kochon, Ti Mouton 160 °F 

‐ Poul, Kodenn, Kanna 165 °F

• Sè vi ak yon tèmomèt manje pou asire ke manje yo 

fini. Ou pa ka toujou we ak je ou.

4. Fredi 

Mete manje nan frijidè touswit.

• Reg 2‐edtan: Mete manje nan frijidè a nan frizè nan 2 

èdtan apre ou fin kwit manje oswa achte nan magazen 

an. Fe sa nan 1 edtan si li se 90 degres oswa pi cho 

deyo.

• Pa janm deglase manje pa senpleman soti li nan 

frigide. Deglase manje:

‐ Nan frigide a 

‐ Anba dlo fret 

‐ Nan mikwo ond 

• Marin manje nan frigide a.
Poukisa ou ta dwe pran swen sou sekirite manje?

Chak ane milyon de moun vin malad nan maladi manje. Maladi manje ka lakòz ou santi tankou ou gen 

grip la. Maladi manje ka lakòz pwoblèm sante grav, menm lanmò.

Sekirite Manje Lakay Ou

Panse ou gen yon maladi manje? 

Rele doktè ou epi jwenn swen medikal touswit.

• Sove pake, bwat, oswa katon manje a.

• Rele USDA nan 1-888-674-6854 pou vyann, bèt volay, oswa ze.

• Rele FDA nan 1 866 300 4374 pou tout lòt manje yo.

• Rele depatman sante lokal ou a si ou panse ou te vin malad nan manje ou te manje nan yon 

restoran oswa lòt machann manje.

Ki moun ki nan risk? 

Nenpòt moun ka vin malad nan manje manje gate. Gen kèk moun ki gen plis chans pou yo vin malad 

nan maladi manje.

• Fanm Ansent

• Moun ki pi gran

• Moun ki gen sèten kondisyon sante tankou kansè, HIV/SIDA, dyabèt, ak maladi ren

Gen kèk manje ki pi riske pou moun sa yo. Pale ak doktè ou oswa lòt founisè sante sou ki manje ki 

san danje pou ou manje.

Fèy enfòmasyon sa te devlope pa Biwo FDA nan Sante Fanm.

Pou jwenn lot resous sante pou fanm, ale nan:

www.fda.gov/womens

Sekirite Manje Lakay Ou (HAITIAN CREOLE) 2021
Russel SMITH Jr. and Teresa Smith, Appellant, v. WELLS FARGO BANK, etc., Appellee.

No. 1D18-2903

District Court of Appeal of Florida, First District.

July 12, 2019

**DECISION WITHOUT PUBLISHED OPINION**

Affirmed.
EXHIBIT 4.1

         

         

        CUSIP


        SMSA PALESTINE ACQUISITION CORP.


        


        INCORPORATED UNDER THE LAWS OF THE STATE OF DELAWARE


         


        


        	
                	
                	
                    SEE REVERSE FOR

                	
                
	
                	
                    COMMON STOCK 

                	
                    CERTAIN DEFINITIONS

                	
                
	
                	 	
                	
                
	
                	 	
                	
                
	
                	
                    SPECIMEN

                	
                	
                


        

        


        

         

         

        This

        certifies

        that

         

         

         

         

         

         

         

        is the owner of


         


         


        

         

         

        FULLY PAID AND NON-ASSESSABLE SHARES OF THE COMMON STOCK, $0.001 PAR VALUE, OF


        SMSA PALESTINE ACQUISITION CORP.


        


        (hereinafter called the "Corporation"), transferable on the books of the Corporation by the holder hereof in person or by duly authorized attorney, upon surrender of the Certificate properly endorsed. This certificate and the shares represented hereby are issued and shall be held subject to all the provisions of the Certificate of
        Incorporation and the Bylaws of the Corporation, as amended (copies of which are on file at the office of the Transfer Agent), to all of which the holder of this Certificate by acceptance hereof assents. This Certificate is not valid unless countersigned and registered by the Transfer Agent and Registrar. Witness the facsmile seal of the Corporation and the facsimile signatures of its duly authorized officers.


         


        


        	DATE:	 	 	 	 	 
	 	
                
	 	
                
	
                	
                      [CORPORATE SEAL OMITTED]

                	 	 
	 	
                
	 	
                
	 	
                
	
                	 	 Countersigned:	 	 
	PRESIDENT	 	 	SECURITIES TRANSFER CORPORATION	 	 
	
                	 	 	P.O. Box 701629	 	 
	
                	 	 	Dallas, TX 75370	 	 
	
                	 	 	By:	 	 
	
                	 
	
                	
                
	SECRETARY	 	 	___________________________________	 	 
	
                	 	 	TRANSFER AGENT-AUTHORIZED SIGNATURE
Jussi Kustaa KIVISTO, petitioner, v. EXECUTIVE COMMITTEE OF the UNITED STATES DISTRICT COURT FOR the NORTHERN DISTRICT OF ILLINOIS.

No. 12-1095.

Supreme Court of the United States

May 13, 2013.

*2383Petition for writ of certiorari to the United States Court of Appeals for the Seventh Circuit denied.
Ira Jay DANIELS, petitioner, v. Sandra PENNYWELL, Acting Warden.

No. 12-9142.

Supreme Court of the United States

May 13, 2013.

Petition for writ of certiorari to the United States Court of Appeals for the Ninth Circuit denied.
1

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

The Law Offices of John L. Burris

7677 Oakport Street, Suite 1120

Oakland, California 94621

Telephone: (510) 839-5200

UNITED STATES DISTRICT COURT

NORTHERN DISTRICT OF CALIFORNIA

BRANDON SIMPSON,

 Plaintiff,

v.

CITY AND COUNTY OF SAN 

FRANCISCO, et al.

 Defendants.

Case: 17-00133 KAW

WRIT OF HABEAS CORPUS AND

TESTIFICANDUM

It is hereby ordered that the Clerk of the Court issue a Writ of Habeas Corpus and 

Testificandum for the person of BRANDON SIMPSON, PFN BFI303, whose place of 

custody and jailor are set forth in the Writ, attached hereto, as the presence of the said person 

will be necessary at the Settlement Conference proceedings on June 27, 2017, at 10:00 a.m., 

in the above entitled case and thereafter as may be required. 

June 19, 2017 ________________________________

Date Honorable Judge Laurel Beeler 

Case 4:17-cv-00133-KAW Document 36 Filed 06/20/17 Page 1 of 1
Eddie MOBLEY, aka Eddie Country, petitioner, v. UNITED STATES.

No. 12-9882.

Supreme Court of the United States

May 28, 2013.

Petition for writ of certiorari to the United States Court of Appeals for the Fourth Circuit denied.
Lines pISall aad oi cS LbLS Saal 6 ghd

GLa JS cod Quill! 4glea (8 adlas
ON Slat} 6) oad gh gall) Q Gas Y

o

5 deal PERT on (499 |u| Ati Ay youll
6 gill DSU
TAKING 

MEDICINES 

OR VITAMINS? 

1

2

3

4

5

Get more tips:

www.fda.gov/collegewomen

AVOID COMMON MISTAKES BY:

Following directions

Asking questions

Not using expired medicines

Not sharing medicines

Storing medicines safely
Regulatory Procedures Manual March 2009 Chapter 7 Recall Procedures 

___________________________________________________________________________

7-58

Exhibit 7-4 

MODEL RECALL LETTER (GENERIC, ALL CENTERS) 

<COMPANY LETTERHEAD> 

URGENT: < Insert FOOD, DRUG, MEDICAL DEVICE, BIOLOGIC, COSMETIC, etc.> RECALL 

 <DATE> 

<Contact name or Dept.> 

<Firm Name> 

<Address> 

<City/state/zip> 

Dear < >: 

This is to inform you of a product recall involving: 

 <Insert: PRODUCT NAME, BRAND NAME, DESCRIPTION, UPC 

 CODES, LOT NUMBERS> 

See enclosed product label <for ease in identifying the product at retail/user level>. 

This recall has been initiated due to <problem>. Use of <or consumption of> this product may 

<include any potential health hazard>. 

We began shipping this product on <date> (or) This product was shipped to you on <date>. (If 

possible, provide consignee with shipping dates and quantities shipped.) 

Immediately examine your inventory and quarantine product subject to recall. In addition, if 

you may have further distributed this product, please identify your customers and notify them 

at once of this product recall. Your notification to your customers may be enhanced by 

including a copy of this recall notification letter, or <Enclosed is a letter you should use in 

notifying your customers>. 

[Your notification must include instructions on what customers should do with the recalled 

product.] 

This recall should be carried out to the <wholesale>, <retail>, <consumer>, <user> level. 

Your assistance is appreciated and necessary to prevent <i.e. consumer illness or patient 

harm>. 

Please complete and return the enclosed response form as soon as possible. 

If you have any questions, call <name and telephone number>. 

This recall is being made with the knowledge of the Food and Drug Administration. 

.
 Regulatory Procedures Manual March 2009 Chapter 7 Recall Procedures 

___________________________________________________________________________

7-59

 Name 

 Title 

Enclosure(s)
In re Daniel Eric COBBLE, petitioner.

No. 12-9529.

Supreme Court of the United States

June 3, 2013.

Motion of petitioner for leave to proceed *in forma pauperis* denied, and petition for writ of mandamus dismissed. See Rule 39.8.
United States District Court

For the Northern District of California

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

ORDER CONTINUING HEARING DATE—No. C-05-01668 RMW; 05-01766 RMW

MAG

United States District Court

For the Northern District of California

E-FILED on 2/25/08

IN THE UNITED STATES DISTRICT COURT

FOR THE NORTHERN DISTRICT OF CALIFORNIA

SAN JOSE DIVISION

COMPUTER CACHE COHERENCY

CORPORATION,

Plaintiff,

v.

VIA TECHNOLOGIES, INC. and VIA

TECHNOLOGIES, INC. (USA),

Defendants.

No. C-05-01668 RMW

ORDER CONTINUING HEARING DATE

COMPUTER CACHE COHERENCY

CORPORATION,

Plaintiff,

v.

INTEL CORPORATION,

Defendant.

No. C-05-01766 RMW

ORDER CONTINUING HEARING DATE

On the court's own motion, Plaintiff's Motion for Leave to File Amended Complaint in Case

No. 05-01766 and Plaintiff’s Motion to Dismiss Defendant's Motion for Summary Judgment Or,
United States District Court

For the Northern District of California

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

ORDER CONTINUING HEARING DATE—No. C-05-01668 RMW; 05-01766 RMW

MAG 2

Alternatively, Continue Defendant’s Motion Pending Completion of Additional Discovery in Case

No. 05-01668, both previously set for February 15, 2008, have been continued to March 21, 2008.

DATED: 2/22/08

RONALD M. WHYTE

United States District Judge
United States District Court

For the Northern District of California

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

ORDER CONTINUING HEARING DATE—No. C-05-01668 RMW; 05-01766 RMW

MAG 3

Notice of this document has been electronically sent to:

Counsel for Plaintiff:

Roderick G. Dorman dormanr@hbdlawyers.com

Lawrence M. Hadley hadleyl@hbdlawyers.com

Omer Salik saliko@hbdlawyers.com

Counsel for Defendants:

James P. Bennett jbennett@mofo.com

Juanita R. Brooks brooks@fr.com

Joseph V Colaianni , Jr Colaianni@fr.com

Paul Forrest Coyne pcoyne@mofo.com

John Michael Farrell jfarrell@fr.com

Karl J. Kramer kkramer@mofo.com,sdevol@mofo.com

Jennifer A. Ochs jochs@wsgr.com,lwang@wsgr.com

Timothy Wayne Riffe Riffe@fr.com,conway@fr.com,gwilliams@fr.com

Counsel are responsible for distributing copies of this document to co-counsel that have not

registered for e-filing under the court's CM/ECF program.

Dated: 2/25/08 /s/ MAG

Chambers of Judge Whyte
Timothy Justin TACY, Sr., Appellant/Petitioner(s), v. STATE of Florida, Appellee/Respondent(s).

CASE NO.: 2D19-2416

District Court of Appeal of Florida, Second District.

July 17, 2019

**DECISION WITHOUT PUBLISHED OPINION**

Denied.
P/NP: Present, Not Present

 C/NC: Custody, Not in Custody 

 I: Interpreter 

Adriana M. Kratzmann

Courtroom Deputy

Original: Efiled 

CC: 

UNITED STATES DISTRICT COURT

NORTHERN DISTRICT OF CALIFORNIA

CRIMINAL MINUTES

Date: June 29, 2020 Time: 1:45-2:05 pm

Total Time: 20 Mins.

Judge: Edward J. Davila

Case No.: 17-cr-00068-EJD2Case Name: UNITED STATES v. Tomas Rivera(P)(C)(I)

Attorney for Plaintiff: Stephen Meyer

Attorney for Defendant: Michael Whelan

Deputy Clerk: Adriana M. Kratzmann Court Reporter: Irene Rodriguez

Interpreter: Lupita Arce(Spanish) Probation Officer: Kyle Pollak

PROCEEDINGS – SENTENCING (In-Court Zoom Hybrid Webinar)

Defendant is present, in-custody and assisted by the Spanish interpreter. Hearing held.

The Court GRANTED variance.

Defendant is hereby committed to the custody of the Bureau of Prisons (BOP) to be imprisoned 

for a term of 324 months. This term consists of 324 months as to Ct. 1 of the Second Superseding 

Indictment (Dkt. 147 filed 8/16/2018) and 240 months on Ct. 2, and 120 months on Ct. 11, said 

term to be served concurrent to one another. 

The Court imposed a 5-year term of supervised release. This term consists of 5 years on Ct. 1 and 

3 years as to Cts. 2 and 11, said terms shall run concurrently to one another. The Court adopts the 

Probation Officer’s recommendations for standard and special conditions (SEE JUDGMENT).

$300 Special Assessment Fee imposed due immediately; Fine waived;

Defendant is remanded to the custody of the BOP;

The Court makes the following recommendation to the BOP: 1) The defendant be designated to a 

facility as close to Santa Cruz, California as possible where his family resides; and 2)Defendant 

participate in the RDAP program.

The Government orally requests that the Court dismiss the underlying open Counts in the previous 

Indictments. The Court ordered those Indictments and those counts dismissed as to this defendant.

The Court orders the defendant’s interest in the forfeiture items be forfeited.

Case 5:17-cr-00068-EJD Document 346 Filed 06/29/20 Page 1 of 1
심장 건강

심장병은 남성에게만 영향을 미친다고 

생각할 수 있습니다. 이것은 사실이 

아닙니다. 심장병은 여성에게 있어 가장 

사망을 많이 일으키게 하는 원인입니다.

미국 식품의약국은 귀하의 심장에 

대하여 좋은 결정을 할 수 있도록 도울 수 

있는 조언을 드립니다.

미국 식품의약국 여성 건강 담당 부서

www.fda.gov/womenshearthealth 

아스피린에 대하여 

올바르게 알아두십시오.

심장마비나 뇌졸증을 예방하기 위해 아스피린을 매

일 복용하는 것이 모두에게 적합한 것은 아닙니다.

• 아스피린을 복용해야 하는지는 의료서비스

제공자에게 문의하십시오.

• 만약 아스피린이 여러분에게 적합하다면 다음

사항을 알아보십시오:

 ‐얼마큼 복용해야 하는지. 

 ‐얼마나 자주 복용해야 하는지.

 ‐얼마나 오랫동안 아스피린을 복용해야 하는지.

어떤제품은 아스피린과 다른 성분이 같이 들어 

있어 장기복용으로 적합하지 않습니다.

• 여러분이 복용하는 모든 약과 보충제를 의료서비스

제공자에게 알려 주십시오. 만약 특정 약이나 

비타민제,혹은 약초를 복용하면서 함께 아스피린을 

복용할 경우출혈의 위험이 높아질 수 있습니다.

심장마비의 징후를 알

아 두십시오.

여성에게 나타나는 심장마비의 징후는 남성과 다

를 수 있습니다.

• 견갑골 사이의 등 혹은 흉부의 무거운 통증이나

압박

• 날카로운 상반신 통증

• 호흡 곤란

• 식은땀 발생

• 특이하거나 원인을 알 수 없는 피로감

• 현기증이나 어지럼증을 느낌

• 복통 (메스꺼움)
심장 건강

이 정보지는 미국 식품의약국 여성 건강 담당 부서에서 제작되었습니다.

여성 건강에 대한 자세한 정보를 얻기 위해서는 미국 식품의약국 웹사이트를 방문하십시오:

www.fda.gov/womenshearthealth

건강 상태를 관

리하십시오.

고혈압이나 당뇨, 고콜레스테롤과 

같은 흔한 건강 문제가 심장 질환

에 걸릴 위험을 높일 수 있습니다.

• 약은 용법대로 복용하십시오. 의사의

허락이 없는 한 약 복용을 중지하지 

마십시오.

• 당뇨가 있다면 혈당치를 측정하십시오.

• 혈압과 콜레스테롤 수치를 확인하십시오.

• 임신 중 건강 상태를 어떻게 관리할

것인지에 대하여 의사에게 문의하십시오.

• 일부 여성들은 심장의 기능을 돕기

위해 기기가 필요합니다 . 여러분의 

심장 문제와 관련해 어떠한기기가 가장 

좋을지에 대하여 의사와 상담하십시오.

2016

심장에 좋은 식습관

을 가지십시오.

식품 라벨에 적혀 있는 영양 정보 (nutrition facts) 는 여러분이 건강한 음식을 선

택할 수 있도록 도와줍니다.

• 저염 (low salt)’이나 ‘저나트륨 (low

sodium)’인 음식을 선택하십시오.

• ’트랜스 지방 (trans fat)’이 들어간 음식은

자제하십시오. 트랜스 지방의 과다 섭취는 

심장마비를 일으킬 수 있습니다.

• 당분 (sugar) 섭취량을 줄이십시오.

당분은 설탕 (sugar) 외에도 ‘포도당 

(glucose)’, ‘과당 (fructose)’, ‘ 자당 

(sucrose)’, 혹은 ‘옥수수 시럽 (corn 

syrup)’ 으로도 표기될 수 있습니다.

심장 건강 (KOREAN)
William SMITH, petitioner, v. Alvin FRIEDMAN, et al.

No. 12-1004.

Supreme Court of the United States

April 22, 2013.

Petition for writ of certiorari to the Court of Special Appeals of Maryland denied.
Exhibit 10.1


 


Amendment to the

FOSTER WHEELER INC.

Directors’ Stock Option Plan


 


The Foster Wheeler Inc. Directors’ Stock Option Plan
(the “Plan”) is hereby amended as follows, pursuant to resolutions adopted by
the Board of Directors of Foster Wheeler Ltd. and its Compensation Committee at
their meetings held December 8, 2008, and resolutions adopted by the Board
of Directors of Foster Wheeler Inc. dated January 23, 2009:


 


1.                                       References
in the Plan to “Parent” are replaced with “Foster Wheeler AG.”


 


2.                                       The
following new Section 11 is added to the Plan:


 


11.           Redomestication.  Foster Wheeler Ltd. moved the place of
organization of the parent company of its group of companies from Bermuda to
Switzerland by means of a scheme of arrangement (“Scheme of Arrangement”)
between Foster Wheeler Ltd. and Foster Wheeler AG, a wholly-owned subsidiary of
Foster Wheeler Ltd. registered in Switzerland, and certain related agreements
described in Foster Wheeler Ltd.’s Proxy Statement for the Special
Court-Ordered Meeting of Common Shareholders held on January 27,
2009.  Effective upon the completion of
the Scheme of Arrangement, shares of Foster Wheeler AG will be issued, held,
made available, or used to measure benefits as appropriate under the Plan in
lieu of common shares of Foster Wheeler Ltd. with respect to all outstanding
awards.


 


3.                                       This
Amendment shall take effect upon completion of the Scheme of Arrangement (as
described in the resolutions adopted on December 8, 2008 by the Board of
Directors of Foster Wheeler Ltd.) and shall apply to all awards outstanding on
such date.


 


IN WITNESS WHEREOF,
Foster Wheeler Inc. has caused this Amendment to the Plan to be executed.


 


	
   

  	
  FOSTER WHEELER INC.

  
	
   

  	
   

  
	
   

  	
   

  
	
   

  	
  By:

  	
  /s/ Peter J. Ganz

  
	
   

  	
  Name: 

  	
  Peter J. Ganz

  
	
   

  	
  Title:

  	
  Executive Vice President
Robin Roy MARTELL, petitioner, v. UNITED STATES.

No. 12-9210.

Supreme Court of the United States

April 15, 2013.

Petition for writ of certiorari to the United States Court of Appeals for the Ninth Circuit denied.
[Federal Register Volume 60, Number 81 (Thursday, April 27, 1995)]
[Notices]
[Page 20682]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 95-10351]



-----------------------------------------------------------------------

FEDERAL EMERGENCY MANAGEMENT AGENCY
[FEMA-1008-DR]


California; Amendment to Notice of a Major Disaster Declaration

AGENCY: Federal Emergency Management Agency (FEMA).

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: This notice amends the notice of a major disaster for the 
State of California (FEMA-1008-DR), dated January 17, 1994, and related 
determinations.

EFFECTIVE DATE: April 18, 1995.

FOR FURTHER INFORMATION CONTACT:
Pauline C. Campbell, Response and Recovery Directorate, Federal 
Emergency Management Agency, Washington, DC 20472, (202) 646-3606.

SUPPLEMENTARY INFORMATION: Notice is hereby given that, effective this 
date and pursuant to the authority vested in the Director of the 
Federal Emergency Management Agency under Executive Order 12148, I 
hereby appoint Laurence Zensinger of the Federal Emergency Management 
Agency to act as the Federal Coordinating Officer for this declared 
disaster.
    This action terminates my appointment of William C. Tidball as 
Federal Coordinating Officer for this disaster.

(Catalog of Federal Domestic Assistance No. 83.516, Disaster 
Assistance.)
James L. Witt,
Director.
[FR Doc. 95-10351 Filed 4-26-95; 8:45 am]
BILLING CODE 6718-02-M
1

UNITED STATES DISTRICT COURT

NORTHERN DISTRICT OF CALIFORNIA

RELATED CASE ORDER

A Motion for Administrative Relief to Consider Whether Cases Should be Related or a 

Sua Sponte Judicial Referral for Purpose of Determining Relationship (Civil L.R. 3-12) has been 

filed. The time for filing an opposition or statement of support has passed. As the judge assigned 

to case 

17-cv-00485-WHO

City and County of San Francisco v. Donald J. Trump

I find that the more recently filed case(s) that I have initialed below are related to the case 

assigned to me, and such case(s) shall be reassigned to me. Any cases listed below that are not 

related to the case assigned to me are referred to the judge assigned to the next earliest filed case 

for a related case determination.

Case Title Related Not Related

19-cv-06189-LB State of California v. Barr X

ORDER

The parties are instructed that all future filings in any reassigned case are to bear the 

initials of the newly assigned judge immediately after the case number. Any case management 

conference in any reassigned case will be rescheduled by the Court. The parties shall adjust the 

dates for the conference, disclosures and report required by FRCivP 16 and 26 accordingly. 

Unless otherwise ordered, any dates for hearing noticed motions are vacated and must be renoticed by the moving party before the newly assigned judge; any deadlines set by the ADR Local 

Rules remain in effect; and any deadlines established in a case management order continue to 

govern, except dates for appearance in court, which will be rescheduled by the newly assigned 

judge.

Dated: October , 2019 By: 

William H. Orrick

United States District Judge

Case 3:17-cv-00485-WHO Document 237 Filed 10/08/19 Page 1 of 1